ENTITY
Innovent Biologics Inc

Innovent Biologics Inc (1801 HK)

357
Analysis
Health CareChina
Innovent Biologics, Inc. operates as a biopharmaceutical company. The Company develops, manufactures, and distributes monoclonal antibody drug candidates for the treatment of oncology, ophthalmology, autoimmune, cardiovascular, and other diseases. Innovent Biologics serves customers in China.
more
Refresh
03 Apr 2022 08:48

China Healthcare Weekly (Apr.1)- Lower Budget of Public Hospitals, IPO Environment, Impatient Market

The NHC's budget for 2022 further reduced the expenditure of public hospitals, affecting the payment cycle; For investors in both primary and...

Logo
224 Views
Share
02 Apr 2022 19:32

Shanghai Junshi Bioscience (1877 HK): Uncertainties Prevailing Ahead of First U.S. Drug Approval

Going by the FDA’s recent action, Junshi Bioscience’s toripalimab has a chance to get rejected by the FDA. It may miss the approval timeline....

Logo
318 Views
Share
bullishBeiGene
08 Mar 2022 08:57

BeiGene Ltd (6160.HK/688235.CH) - There Is No Way to Retreat

BeiGene’s cash flow can't keep up with the cash burn rate in long term.So BeiGene has to deliver solid commercialization results,...

Logo
349 Views
Share
06 Mar 2022 09:09

China Healthcare Weekly (Mar.4)-Innovative Drug Cyclical Nature, Pet Vaccine Mkt, Legend Bio, Junshi

Junshi’s PD-1 result in April is more representative to judge FDA's attitude and globalization logic. We probably are at the tail end of mab drug...

Logo
246 Views
Share
27 Feb 2022 09:25

China Healthcare Weekly (Feb.25)-Assisted Reproduction, Medical Device Co. Globalization, New Growth

Assisted reproduction is covered by medical insurance; We analyzed the benchmark of medical device companies' globalization, clarify the...

Logo
197 Views
Share
x